The role of PET/CT as a prognosticator and outcome predictor in lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Collins LG, Haines C, Perkel R, et al. Lung cancer: diagnosis and management. Am Fam Physician. 2007;75(1):56–63.
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22(2):330–353.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Fischer BM, Dooms C, et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004;5(9):531–540.
   PubMed Web of Science ®Google Scholar
• Mac Manus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys. 2008;72(5):1298–1306.
   PubMed Web of Science ®Google Scholar
• Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys. 2005;63(4):1016–1023.
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Hicks RJ. The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. Semin Nucl Med. 2012;42(5):308–319.
   PubMed Web of Science ®Google Scholar
• Opoka L, Szołkowska M, Podgajny Z, et al. Assessment of recurrence of non-small cell lung cancer after therapy using CT and Integrated PET/CT. Pneumonol Alergol Pol. 2013;81(3):214–220.
   PubMedGoogle Scholar
• Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285(7):914–924.
   PubMed Web of Science ®Google Scholar
• Van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388–1393.
   PubMed Web of Science ®Google Scholar
• Verhagen AF, Bootsma GP, Tjan-Heijnen VCG, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer. 2004;44(2):175–181.
   PubMed Web of Science ®Google Scholar
• Ulaner GA, Lyall A. Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT. Radiographics. 2013;33(6):1817–1834.
   PubMed Web of Science ®Google Scholar
• Abdulla S, Salavati A, Saboury B, et al. Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study. Eur J Nucl Med Mol Imaging. 2014;41(2):350–356.
   PubMed Web of Science ®Google Scholar
• Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2(3):159–171.
   PubMedGoogle Scholar
• Vees H, Senthamizhchelvan S, Miralbell R, et al. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging. 2009;36(2):182–193.
   PubMed Web of Science ®Google Scholar
• Zaidi H, Abdoli M, Fuentes CL, et al. Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2012;39(5):881–891.
   PubMed Web of Science ®Google Scholar
• Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging. 2010;37(11):2165–2187.
   PubMed Web of Science ®Google Scholar
• Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17(1):115–122.
   PubMed Web of Science ®Google Scholar
• Chung MK, Jeong H-S, Park SG, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15(18):5861–5868.
   PubMed Web of Science ®Google Scholar
• Xie P, Yue J-B, Zhao H-X, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2010;136(6):883–889.
   PubMed Web of Science ®Google Scholar
• Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17(10):2787–2794.
   PubMed Web of Science ®Google Scholar
• Arslan N, Tuncel M, Kuzhan O, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011;25(6):406–413.
   PubMed Web of Science ®Google Scholar
• Houshmand S, Salavati A, Hess S, et al. An update on novel quantitative techniques in the context of evolving whole-body PET imaging. PET Clin. 2015;10(1):45–58.
   PubMedGoogle Scholar
• Matthies A, Hickeson M, Cuchiara A, et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43(7):871–875.
   PubMed Web of Science ®Google Scholar
• Chen HH, Lee B-F, Su W-C, et al. The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013;40(10):1478–1485.
   PubMed Web of Science ®Google Scholar
• Houshmand S, Salavati A, Basu S, et al. The role of dual and multiple time point imaging of FDG uptake in both normal and disease states. Clin Transl Imaging. 2014;2(4):281–293.
   Google Scholar
• UyBico SJ, Wu CC, Suh RD, et al. Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics. 2010;30(5):1163–1181.
   PubMed Web of Science ®Google Scholar
• Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e211S–250S.
   PubMed Web of Science ®Google Scholar
• Gregory DL, Hicks RJ, Hogg A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53(7):1007–1015.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Khiewvan B, Fox PS, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41(5):906–914.
   PubMed Web of Science ®Google Scholar
• Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31(12):1614–1620.
   PubMed Web of Science ®Google Scholar
• Azad A, Chionh F, Scott AM, et al. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol. 2010;12(4):443–451.
   PubMed Web of Science ®Google Scholar
• Blum R, MacManus MP, Rischin D, et al. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol. 2004;27(2):164–171.
   PubMed Web of Science ®Google Scholar
• Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3):1037–1057.
   PubMed Web of Science ®Google Scholar
• Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28(3):173–185.
   PubMed Web of Science ®Google Scholar
• Lyons G, Quadrelli S, Silva C, et al. Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T factor. J Thorac Oncol. 2008;3(9):989–993.
   PubMed Web of Science ®Google Scholar
• Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43(1):39–45.
   PubMed Web of Science ®Google Scholar
• Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83(5):918–924.
   PubMed Web of Science ®Google Scholar
• Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22(16):3255–3260.
   PubMed Web of Science ®Google Scholar
• Cerfolio RJ, Bryant AS, Ohja B, et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130(1):151–159.
   PubMed Web of Science ®Google Scholar
• Eschmann SM, Friedel G, Paulsen F, et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging. 2006;33(3):263–269.
   PubMed Web of Science ®Google Scholar
• Borst GR, Belderbos JSA, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41(11):1533–1541.
   PubMed Web of Science ®Google Scholar
• Hellwig D, Graeter TP, Ukena D, et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg. 2004;128(6):892–899.
   PubMed Web of Science ®Google Scholar
• Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(33):8362–8370.
   PubMed Web of Science ®Google Scholar
• Hellwig D, Gröschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33(1):13–21.
   PubMed Web of Science ®Google Scholar
• Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med. 2001;42(11):1605–1613.
   PubMed Web of Science ®Google Scholar
• Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78(6):1903–1909. discussion 1909
   PubMed Web of Science ®Google Scholar
• Pöttgen C, Levegrün S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006;12(1):97–106.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhou T, Ma L, et al. Standard uptake value and metabolic tumor volume of (1)(8)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38(9):1628–1635.
   PubMed Web of Science ®Google Scholar
• Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):328–333.
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21(7):1285–1292.
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer. 2005;49(1):95–108.
   PubMed Web of Science ®Google Scholar
• Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21(14):2651–2657.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol. 1998;9(11):1193–1198.
   PubMed Web of Science ®Google Scholar
• Soussan M, Chouahnia K, Maisonobe J-A, et al. Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy. Eur J Nucl Med Mol Imaging. 2013;40(5):668–676.
   PubMed Web of Science ®Google Scholar
• Davies A, Tan C, Paschalides C, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer. 2007;55(1):75–78.
   PubMed Web of Science ®Google Scholar
• Nair VS, Barnett PG, Ananth L, et al. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest. 2010;137(5):1150–1156.
   PubMed Web of Science ®Google Scholar
• De Geus-Oei L-F, Van Der Heijden HFM, Corstens FHM, et al. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110(8):1654–1664.
   PubMed Web of Science ®Google Scholar
• Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23(6):1136–1143.
   PubMed Web of Science ®Google Scholar
• Jeong H-J, Min J-J, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun. 2002;23(9):865–870.
   PubMed Web of Science ®Google Scholar
• Dhital K, Saunders CA, Seed PT, et al. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18(4):425–428.
   PubMed Web of Science ®Google Scholar
• Hanin F-X, Lonneux M, Cornet J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33(5):819–823.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Cho A, Cho BC, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res. 2009;15(7):2426–2432.
   PubMed Web of Science ®Google Scholar
• Uehara H, Tsutani Y, Okumura S, et al. Prognostic role of positron emission tomography and high-resolution computed tomography in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2013;96(6):1958–1965.
   PubMed Web of Science ®Google Scholar
• Tomita M, Shimizu T, Ayabe T, et al. Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer. Asia Pac J Clin Oncol. 2012;8(3):244–247.
   PubMed Web of Science ®Google Scholar
• Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(1):27–38.
   PubMed Web of Science ®Google Scholar
• Hoang JK, Hoagland LF, Coleman RE, et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;26(9):1459–1464.
   PubMed Web of Science ®Google Scholar
• Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932–945.
   PubMed Web of Science ®Google Scholar
• Ohri N, Duan F, Machtay M, et al. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. J Natl Cancer Inst. 2015;107(4):244–247.
   Google Scholar
• Salavati A, Duan F, Houshmand S, et al. The impact of partial volume effect correction on predictive value of FDG-PET/CT volumetrics in patients with locally advanced Non-small Cell Lung Cancer (NSCLC): a secondary analysis of ACRIN 6668/RTOG 0235. Journal of Nuclear Medicine. 2015;56(3):183.
   PubMedGoogle Scholar
• Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(1):49–57.
   PubMed Web of Science ®Google Scholar
• Ball DL, Fisher R, Burmeister B, et al. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol. 2006;1(7):667–672.
   PubMed Web of Science ®Google Scholar
• Lee P, Bazan JG, Lavori PW, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin Lung Cancer. 2012;13(1):52–58.
   PubMed Web of Science ®Google Scholar
• Davison J, Mercier G, Russo G, et al. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR Am J Roentgenol. 2013;200(3):635–640.
   PubMed Web of Science ®Google Scholar
• Kim K, Kim S-J, Kim I-J, et al. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33(6):613–620.
   PubMed Web of Science ®Google Scholar
• van Loon J, Offermann C, Ollers M, et al. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother Oncol. 2011;99(2):172–175.
   PubMed Web of Science ®Google Scholar
• Melloni G, Gajate AMS, Sestini S, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. Eur J Surg Oncol. 2013;39(11):1254–1261.
   PubMed Web of Science ®Google Scholar
• Chen HHW, Chiu N-T, Su W-C, et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264(2):559–566.
   PubMed Web of Science ®Google Scholar
• Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257(2):364–370.
   PubMed Web of Science ®Google Scholar
• Yan H, Wang R, Zhao F, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Acta Radiol. 2011;52(6):646–650.
   PubMed Web of Science ®Google Scholar
• Oh J-R, Seo J-H, Chong A, et al. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(6):925–935.
   PubMed Web of Science ®Google Scholar
• Zhu D, Ma T, Niu Z, et al. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73(3):332–337.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wroblewski K, Jiang Y, et al. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015;89(1):43–49.
   PubMed Web of Science ®Google Scholar
• Houseni M, Chamroonrat W, Zhuang J, et al. Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med. 2010;51(4):535–542.
   PubMed Web of Science ®Google Scholar
• Xiu Y, Bhutani C, Dhurairaj T, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med. 2007;32(2):101–105.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42(9):1412–1417.
   PubMed Web of Science ®Google Scholar
• Kim S-J, Kim Y-K, Kim IJ, et al. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC). Radiother Oncol. 2011;98(1):105–108.
   PubMed Web of Science ®Google Scholar
• Satoh Y, Nambu A, Onishi H, et al. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Eur J Radiol. 2012;81(11):3530–3534.
   PubMed Web of Science ®Google Scholar
• Li L, Hu M, Zhu H, et al. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11(5):335–340.
   PubMed Web of Science ®Google Scholar
• Kahraman D, Holstein A, Scheffler M, et al. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med. 2012;37(11):1058–1064.
   PubMed Web of Science ®Google Scholar
• Kobe C, Scheffler M, Holstein A, et al. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging. 2012;39(7):1117–1127. PMID: 22526960.
   PubMed Web of Science ®Google Scholar
• Yoon SH, Goo JM, Lee SM, et al. PET/MR imaging for chest diseases: review of initial studies on pulmonary nodules and lung cancers. Magn Reson Imaging Clin N Am. 2015;23(2):245–259.
   PubMed Web of Science ®Google Scholar
• Cao JQ, Rodrigues GB, Louie AV, et al. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non–small-cell lung cancer and management of solitary pulmonary nodules. Clin Lung Cancer. 2012;13(3):161–170.
   PubMed Web of Science ®Google Scholar
• Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. J Thorac Oncol. 2012;7(6):1015–1020.
   PubMed Web of Science ®Google Scholar
• Wang Y-T, Huang G. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective. Eur J Radiol. 2012;81(8):e903–909.
   PubMed Web of Science ®Google Scholar
• Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer. 2010;116(21):5030–5037.
   PubMed Web of Science ®Google Scholar